Publications
Detailed Information
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na Ryung Choi | - |
dc.contributor.author | Ju Yeon Kim | - |
dc.contributor.author | Ji Hoon Hong | - |
dc.contributor.author | Moon Haeng Hur | - |
dc.contributor.author | Heejin Cho | - |
dc.contributor.author | Min Kyung Park | - |
dc.contributor.author | Jihye Kim | - |
dc.contributor.author | Yun Bin Lee | - |
dc.contributor.author | Eun Ju Cho | - |
dc.contributor.author | Jeong‑Hoon Lee | - |
dc.contributor.author | Su Jong Yu | - |
dc.contributor.author | Jung‑Hwan Yoon | - |
dc.contributor.author | Yoon Jun Kim | - |
dc.date.accessioned | 2022-05-04T04:26:27Z | - |
dc.date.available | 2022-05-04T04:26:27Z | - |
dc.date.issued | 2022-03-25 | - |
dc.identifier.citation | BMC Gastroenterology, Vol22(1):135 | ko_KR |
dc.identifier.issn | 1471-230X | - |
dc.identifier.uri | https://hdl.handle.net/10371/179608 | - |
dc.description.abstract | In a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvatinib as first-line systemic therapy against uHCC with real-world data in chronic hepatitis B patients.
This retrospective single-center study involved 132 patients with HBV-related uHCC. Propensity score matching (PSM) was used to balance the baseline characteristics, including age, sex, serum alpha-fetoprotein levels, Child–Pugh class, tumor size, and tumor stage. The primary endpoint was overall survival (OS), and the secondary endpoints included progression-free survival (PFS), time to progression (TTP), and tumor response. After PSM, the final analysis included 44 patients treated with lenvatinib and 88 with sorafenib. The OS (7.0 vs 9.2months, p = 0.070) and PFS (4.6 vs 2.4months, p = 0.134) were comparable between the two drugs. Multivariable analysis showed that lenvatinib and sorafenib were not independent prognostic factors of OS (adjusted hazard ratio = 1.41, 95% confidence interval = 0.96–2.08, p = 0.077) after adjustment for baseline alpha-fetoprotein levels, total bilirubin levels, alanine aminotransferase level, performance status, tumor stage, and tumor size. However, the lenvatinib group had a significantly prolonged TTP (5.2 vs 2.5months, p = 0.018) and a higher objective response rate (18.2% vs 4.5%, p = 0.020) and disease control rate (77.3% vs 47.7%, p = 0.001) than the sorafenib group. Our study demonstrated that lenvatinib had a comparable OS and PFS but longer TTP and better tumor response compared to sorafenib in patients with HBV-related uHCC. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Hepatitis B | - |
dc.subject | Chronic | - |
dc.subject | Carcinoma | - |
dc.subject | Hepatocellular | - |
dc.subject | Lenvatinib | - |
dc.subject | Sorafenib | - |
dc.title | Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | https://doi.org/10.1186/s12876-022-02210-3 | ko_KR |
dc.citation.journaltitle | BMC Gastroenterology | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2022-03-27T03:11:18Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 135 | ko_KR |
dc.citation.volume | 22 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.